GLP-1/GIP

The Dual GLP-1/GIP Agonist Peptide is a synthetic 39-amino-acid peptide engineered to simultaneously activate the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Structural modifications including a C20 fatty diacid moiety enhance albumin binding, prolong plasma half-life, and improve its pharmacokinetic profile. This peptide is primarily studied for its balanced dual receptor activity that mimics native GIP and GLP-1 hormones, contributing to improved glucose metabolism and body weight regulation.
Research involving this peptide commonly explores:
• Its dual receptor binding mechanism, involving an α-helical structure that penetrates receptor transmembrane cores, facilitating sustained insulinotropic and anorectic effects.
• The role of lipidation and incorporation of non-standard amino acids in enhancing peptide stability and modulating receptor signaling bias.
• Experimental evaluation in type 2 diabetes mellitus and obesity models focusing on combined glycemic control and weight loss benefits.
• Biased agonism favoring GIP receptor activation, which may reduce gastrointestinal side effects typically associated with GLP-1 receptor activation.

The Dual GLP-1/GIP Agonist Peptide is supplied as a lyophilized powder for laboratory research use only (RUO). It is not intended for diagnostic, therapeutic, or clinical applications and must not be used in humans or animals.

Product details:

• Synonyms: LY3298176, Twincretin, Dual GLP-1/GIP receptor agonist
• Purity: ≥98%
• Molecular Formula: C210H324N48O65
• Molecular Weight: Approximately 4813 Da
• Appearance: White to off-white lyophilized powder

This product is intended exclusively for scientific research and laboratory investigation in compliance with applicable regulatory guidelines.